Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Tepper JE
Berliner Volksbank eG
Ad hoc announcement pursuant to Art.
PSD Bank Rhein-Ruhr eG
* In the Phase III NETTER-2 trial, Lutathera plus octreotide LAR significantly extended median PFS to 22.8 months vs.
PSD Bank Rhein-Ruhr eG
* FDA approval of the company's second US Radioligand Therapy (RLT) manufacturing facility increases RLT production capacity to 250,000 doses in 2024 and beyond * New 70,000-square foot RLT facility is the company's largest and most advanced in the world to date and centrally located in the US to maximize access for patients and treatment centers * With four active RLT manufacturing sites and unconstrained supply, Novartis can sufficiently meet current and future demand as ongoing clinical...
PSD Bank Rhein-Ruhr eG
* Phase III NETTER-2 trial met primary endpoint of improvement in progression- free survival (PFS) and key secondary endpoint of objective response rate (ORR) in patients with Grade 2 and 3 advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) who received first line treatment with Lutathera(®) in combination with long-acting octreotide, versus high-dose long-acting octreotide alone(1,)(2) * Lutathera is the first radioligand therapy (RLT) to demonstrate clinically meaningful...
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Tepper
Contact Tepper, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack